{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:22:57Z","timestamp":1780482177210,"version":"3.54.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Intravesical therapy plays a crucial role in reducing the risk of recurrence and progression in patients with non-muscle invasive bladder cancer (NMIBC). Among the most widely used intravesical treatments is Bacillus Calmette-Gu\u00e9rin (BCG). To enhance therapeutic outcomes, sequential treatment strategies have been explored, including the combination of BCG with Mitomycin C (MMC) delivered via Electromotive Drug Administration (EMDA). In this retrospective clinical study, we report the results of sequential intravesical administration of BCG and MMC administered via EMDA (MMC EMDA) in 25 patients with intermediate- and high-risk NMIBC. Primary tumors were observed in 11 patients, while 14 had recurrent disease. Only one patient experienced recurrence during follow-up, after the 3 months of the therapy, resulting in an overall recurrence rate of 4%. The median follow-up duration was 16 months. In conclusion, our results support and expand the evidence indicating that sequential BCG and MMC EMDA offer a highly effective treatment approach for patients with intermediate- and high-risk NMIBC.<\/jats:p>","DOI":"10.3389\/fonc.2025.1682918","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T04:18:15Z","timestamp":1759897095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Sequential intravesical Bacillus Calmette-G\u00fcerin and mitomycin C applied with electromotive drug administration therapy for non-muscle invasive bladder cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Mirko","family":"Bakula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tvrtko","family":"Hudolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Kulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Zekulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerko","family":"Andelic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Zimak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Cikic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilija","family":"Juric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeljko","family":"Kastelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-015-1739-2","article-title":"Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old","volume":"466","author":"Comp\u00e9rat","year":"2015","journal-title":"Virchows Arch Int J Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"B4","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"CD011935","DOI":"10.1002\/14651858.CD011935.pub2","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14793","article-title":"The epidemiology of bacille Calmette-Gu\u00e9rin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study","volume":"124","author":"Larsen","year":"2019","journal-title":"BJU Int"},{"key":"B9","article-title":"Electromotive delivery of mitomycin C into human bladder wall","volume":"57","author":"Di Stasi","year":"1997","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2016.1210672","article-title":"Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder","volume":"50","author":"Kaasinen","year":"2016","journal-title":"Scand J Urol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12885-015-1431-6","article-title":"BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)","volume":"15","author":"Hayne","year":"2015","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/RRU.S63447","article-title":"Immunotherapy for bladder cancer","volume":"7","author":"Fuge","year":"2015","journal-title":"Res Rep Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J Urol"},{"key":"B16","unstructured":""},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175024","article-title":"Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions","volume":"926","author":"Li","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0389-x","article-title":"Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer","volume":"27","author":"Di Stasi","year":"2009","journal-title":"World J Urol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3\u2009years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.09.016","article-title":"A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer","volume":"41","author":"Melgarejo-Segura","year":"2023","journal-title":"Urol Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5301\/uro.5000197","article-title":"Radiofrequency-induced thermo-chemotherapy effect (RITE) for non muscle invasive bladder cancer treatment: current role and perspectives","volume":"83","author":"Colombo","year":"2016","journal-title":"Urologia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"B23","article-title":"Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies","volume":"59","author":"Di Stasi","year":"1999","journal-title":"Cancer Res"},{"key":"B24","article-title":"Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder","volume":"154","author":"Rintala","year":"1995","journal-title":"Finnbladder Group J Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Di Stasi","year":"2011","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.002","article-title":"Sequential treatment with bacillus calmette-g\u00fcerin (BCG) and mitomycin C administered with electromotive drug administration (EMDA) in patients with high-risk nonmuscle invasive bladder cancer after BCG failure","volume":"21","author":"Sanz G\u00f3mez","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"850.e9","DOI":"10.1016\/j.urolonc.2020.06.031","article-title":"Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure","volume":"38","author":"Juvet","year":"2020","journal-title":"Urol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus calmette-gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/life14070789","article-title":"Intravesical gemcitabine and docetaxel therapy for BCG-na\u00efve patients: A promising approach to non-muscle invasive bladder cancer","volume":"14","author":"Bakula","year":"2024","journal-title":"Life (Basel)"},{"key":"B30","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), version 5.0\n          \n          \n          \n          2017"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1682918\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T04:18:16Z","timestamp":1759897096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1682918\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":30,"alternative-id":["10.3389\/fonc.2025.1682918"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1682918","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"article-number":"1682918"}}